Literature DB >> 10493946

Balance between activated-STAT and MAP kinase regulates the growth of human bladder cell lines after treatment with epidermal growth factor.

H Kawamata1, K Hattori, F Omotehara, D Uchida, S Hino, M Sato, R Oyasu.   

Abstract

Epidermal growth factor (EGF) is a potent mitogen, and its action is mediated by MAP kinase (MAPK). Reportedly EGF activates STAT, induces the expression of p21waf1, and subsequently inhibits the growth of several types of cancer cells. In this study, we used human bladder cancer cells (T24 and RT4), immortalized non-tumorigenic human urothelial cells (1T-1, 1T-2, and 1T-3), and epidermal carcinoma cells (A431). EGF inhibited the growth of T24 and A431, and stimulated the growth of 1T-1, 1T-3 and 1T-2, but did not affect the growth of RT4. EGF activated MAPK strongly in 1T-1, and slightly in A431, T24, 1T-2, and 1T-3 but marginally in RT4. We detected the activation of STAT in T24, 1T-3 and A431 after EGF treatment. EGF enhanced the expression of p21waf1 mRNA in T24, 1T-2, 1T-3 and A431, and activated the p21waf1 promoter in T24 cells. These results suggest that i) EGF inhibits the growth of T24 cells via induction of p21waf1 mediated by STAT, and ii) the balance between the STAT-induced p21waf1 and MAPK activities regulates the growth of human bladder cells after EGF treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493946     DOI: 10.3892/ijo.15.4.661

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line.

Authors:  F Omotehara; H Kawamata; D Uchida; S Hino; K Nakashiro; T Fujimori
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

2.  Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort study.

Authors:  Chonji Fukumoto; Yuta Sawatani; Ryo Shiraishi; Manabu Zama; Michiko Shimura; Tomonori Hasegawa; Yuske Komiyama; Atsushi Fujita; Takahiro Wakui; Hitoshi Kawamata
Journal:  Invest New Drugs       Date:  2021-01-15       Impact factor: 3.850

3.  Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro.

Authors:  Yuta Sawatani; Yuske Komiyama; Koh-Ichi Nakashiro; Daisuke Uchida; Chonji Fukumoto; Michiko Shimura; Tomonori Hasegawa; Ryouta Kamimura; Masayo Hitomi-Koide; Toshiki Hyodo; Hitoshi Kawamata
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.